Effect of A Unani Drug Compound in Helicobacter Pylori Positive Antral Gastritis

Albina¹, Anis Ismail², Iqbal Aziz³

¹Assistant professor, Department of surgery (Jarahat), Faculty of Unani medicine, Aligarh Muslim University, Aligarh, U.P., India. albina7@rediffmail.com
²Professor, Department of surgery (Jarahat), Faculty of Unani medicine, Aligarh Muslim University, Aligarh, U.P., India. Anisismail61.ai@gmail.com
³Professor, Department of surgery (Jarahat), Faculty of Unani medicine, Aligarh Muslim University, Aligarh, U.P., India. mail.iqbalaziz@gmail.com

ABSTRACT

Aim: We undertook this study to find out the effect of a Unani/Herbal drug compound on the antral gastritis/gastritis and its role in the eradication of H.pylori.

Methods: Study was conducted on 220 patients having Helicobacter pylori positive antral/generalized gastritis, confirmed by endoscopy and Rapid urease test. 110 patients were given Unani/Herbal drug compound (Group A) and 110 were given placebo (Group B) for 3 months. After 3 months endoscopy and RUT were repeated to assess the status of antral/generalized gastritis and eradication of Helicobacter pylori bacteria in both the groups.

Results: In our study we found the association between antral gastritis and H.pylori to be 88.7%. In group A patients showed appreciable improvements in symptoms, 96.4% patients in group A got relief from antral gastritis while in group B only 6.4% patients could get relief from gastritis and the difference is highly significant (p < 0.0001), in group A test drug eradicated H.pylori by 98.8% and in group 8.8% eradication was done by placebo. The difference is highly significant (p<0.0001)

Keywords: Antral, Gastritis, Endoscopy, S Helicobacter Pylori, Unan

1. INTRODUCTION

Worldwide chronic gastritis and peptic ulcer disease are most common disorders and antral gastritis is common finding during endoscopy. A close relationship between chronic gastritis and Helicobacter pylori (H.pylori) infection has been reported and about 75% patients with chronic gastritis have been found to have H.pylori infection compared to 10% in those without gastritis [1].

Since the discovery of H.pylori in 1882 BY Dr. Berry Marshall and Dr. Robin Warren in the stomach of patients with gastritis and stomach ulcers, H.pylori has been a focus of clinical and biochemical researches [2].50% or more of world’s population harbour H.pylori in their upper gastrointestinal tract. The infection of H.pylori is more prevalent in developing countries like in India it is as high as 80% and the incidence is decreasing in western countries due to higher hygiene standards and wide spread use of antibiotics [3], [4].

H.pylori bacteria is a common transmittable human pathogen, once infected with this bacteria most of the persons remain asymptomatic. Chief symptoms of infection include abdominal pain, bloating or fullness, dyspepsia or indigestion, decreased hunger and nausea/vomiting. In infected patients disease starts as chronic superficial gastritis, eventually it progresses to atrophic gastritis and then to gastric carcinoma in some cases. Other manifestations of H.pylori infection
include peptic ulcer disease, primary gastric B-cell lymphoma, iron deficiency anaemia and B12 deficiency [5]-[8]. The most accurate way to diagnose antral gastritis caused by H.pylori is to do upper gastrointestinal endoscopy followed by rapid urease test (RUT) by taking a small piece of mucosa of antrum.

The treatment regimens for H.pylori positive antral gastritis are available in modern medicine which include a minimum of 2 antibiotics like amoxicillin, tinidazole or clarithromycin in combination with gastric acid inhibitors [9],[10], but these regimens are not satisfactory due to some other associated problems, like the patient’s compliance, side effects and bacterial resistance, higher cost and recurrence [11]-[15]. Worldwide hundreds of herbal drugs are being used in traditional medicine for eradication of H.pylori and to treat gastritis [16]-[24]. Unani system of medicine has vast treasure of products which have been indicated for the treatment of gastritis [24]. Unani physicians and among them some have been shown to be effective in eradication of H.pylori in vitro and in vivo studies e.g.

Single drugs (Mufrid adviya): Althaea rosa Linn (Khatmi) [25], Alpinia galanga (Khulanjan) [26], Aloe barbadensis (Elva) [27], Anchusa strigosa (Gaozaban) [28], Glycyrrhiza glabra (Asl-us-soos) [29],[30], Withania somnifera (Asgand)[31], Zingiber officinale (Adrak) [32],[33]-[50], Andrographis paniculata wall (Bhui neem) [34], Emblica officinalis (Amla) [35],[36], Picrorhiza kurroa (Kutki)[37], Nigella sativa Linn (Kalonji) [38], Curcuma longa Linn (Haldi) [17],[18],[39], Berberis aristata (Dar hald) [51]-[53], Momordica charantia Linn (Karela) [54], Aegle marmelos correa (Bael) [55], Asparagus racemosus (Satawar) [56], Acacia arabica (Samagh e arab) [57],[58], Myristica fragrans Houtt (Jaiphal) [59], Plantago ovata (Aspghol), Bambusa arundinacea (Tabasheer), Pistacia lenticus Linn (Mastagi). [60],[40],[41]-[49] Compound drugs (Murakkab adviya): Majoon Dabeedulward [61], Qurs e Satawari [62], Qurs e Tabasheer [63],Jawarish e Tabasheer [64],Majoon e zanjbeel, Jawarish e Anarain, Jawarish e Mastagi, Khameera Sandal, Itrifal Aftimoon, Sharbat e Neelofer, Sharbat e Anar, Sharbat e Unnab.[40],[41]-[49],[65]-[74].

We undertook this study to find out the effect of a Unani drug compound (constituents given in table no. 1) on the antral gastritis/gastritis and its role in the eradication of H.pylori.

| TABLE-1 |
| Unani Drugs | Botanical Names | Part Used | Ratio In Each Capsule (Each Cap. Of 500 Mg) |
| Asl-us-soos | Glycyrrhiza glabra | Stem and bark | 1 part |
| Aspaghol musallam | Plantago ovata | Seeds | 2 part |
| Samgh e arabi | Acacia arabica | Dries exudate | 2 part |
| Mastagi | Pistacia lenticus | Resin | 1 part |

2. MATERIAL AND METHOD

This study was conducted within the duration of 2 years (during February 2011 to 2013) in the department of Surgery (Jarahat), Ajmal Khan Tibbya College, AMU, Aligarh. This was a randomized single blind, controlled clinical trial.

2.1. Inclusion Criteria

We included the patients who met the following criteria.

(i) Patients having following symptoms at least for 7 days.
(a) Heart Burn
(b) Nausea
(c) Vomiting
d. Indigestion
c. Abdominal pain
(ii) Patients with antral gastritis, diagnosed by endoscopy.
(iii) H. Pylori positive patients, confirmed by rapid urease test (RUT).
(iv) Age between 10 yrs. To 80 years.

2.2. Exclusion Criteria

We excluded the patients who met with any of the following criteria.
(i) Patients who had NSAIDs or any antibiotics with in the last 4 weeks.
(ii) Any systemic disease (Hepato-renal and pulmonary malfunction)
(iii) Patients with prior history of pyloric stenosis is gastric resection.
(iv) Patients with prior history of peptic ulcer or gastric carcinoma.
(v) Patients with active G.I. haemorrhage, Obstruction a perforation.
(vi) Alcoholic Subjects.
(vii) Pregnancy and lactation.
(viii) Anxiety disorders.
(ix) Bleeding disorders.
(x) HBs Ag +ve and HIV +ve

2.3. Methodology
Permission from the institutional ethical committee was taken before starting the study. A written and well informed consent was taken from the patients before participation into the study. The patients who were having the features of chronic gastritis like heart burn, nausea/vomiting, indigestion, abdominal pain and loss of appetite were screened and they were called for endoscopy, nil orally (fasted overnight). During endoscopy the area of anomaly was documented and at the same time punch biopsy was taken from antrum of the stomach and a rapid unaease test (RUT) was done form the mucosa to confirm the presence or absence of H.Pylori bacteria. Only the patients having antral gastritis and/or generalized gastritis with H. Pylori positive test (RUT) was done form the mucosa to confirm the presence or absence of H.Pylori bacteria. Only the patients having antral gastritis and/or generalized gastritis with H. Pylori positive test (RUT) were enrolled in the study and the selected patients were divided into two groups of group A and group B. Group A was given the Unani Drug compound and group B was given the placebo. Unani drug compound and placebo were given in the dose of 2 capsules twice daily before meals with water for 3 months. In follow up all the patients were called weekly to note down the symptomatic relief and after 3 months of treatment the symptomatic relief was again noted down and endoscopy was repeated by the same endoscopist in our department, changes in the endoscopic findings were documented and RUT was repeated from the mucosa taken from the antrum by biopsy during post-treatment endoscopy for the confirmation presence/absence of H. Pylori.

2.4. Statistical Analysis
We applied Yates corrected Chi square test to analyse the results.

3. RESULTS AND OBSERVATIONS
A total of 329 patients with the complaints of heart burn, nausea/vomiting, indigestion and abdominal pain were screened and it was observed that among screened 329 patients 69.6% (229) patients were found to have antral gastritis and 5.7% (19) were having generalized gastritis and rest were having hiatus hernia, reflux oesophagitis, duodinitis, gastric ulcer in the percentage of 21.8%, 16.7%, 11.5% and 1% respectively (table no.2).

<table>
<thead>
<tr>
<th>Endoscopic finding</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antral gastritis</td>
<td>229</td>
<td>69.6</td>
</tr>
<tr>
<td>Generalized gastritis</td>
<td>19</td>
<td>5.7</td>
</tr>
<tr>
<td>Hiatus hernia</td>
<td>72</td>
<td>21.8</td>
</tr>
<tr>
<td>Reflux oesophagitis</td>
<td>55</td>
<td>16.7</td>
</tr>
<tr>
<td>Duodinitis</td>
<td>38</td>
<td>11.5</td>
</tr>
<tr>
<td>Gastric ulcer at pylorus</td>
<td>03</td>
<td>1.0</td>
</tr>
</tbody>
</table>

After Rapid urease test 220 (66.80%) patients were found to be H.pylori positive antral gastritis/gastritis and rest 109 (33.20%) were H.pylori negative (table no.3), hence the study was conducted on 220 patients.

<table>
<thead>
<tr>
<th>Endoscopic finding</th>
<th>No. of pts</th>
<th>%</th>
<th>1</th>
<th>%</th>
<th>2</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antral/generalized gastritis</td>
<td>248</td>
<td>75.5</td>
<td>220</td>
<td>88.7</td>
<td>28</td>
<td>11.3</td>
</tr>
<tr>
<td>Other findings</td>
<td>81</td>
<td>24.4</td>
<td>70</td>
<td>86.5</td>
<td>11</td>
<td>13.5</td>
</tr>
<tr>
<td>Total</td>
<td>329</td>
<td>100.0</td>
<td>290</td>
<td>88.1</td>
<td>39</td>
<td>11.8</td>
</tr>
</tbody>
</table>
1. No. of pts with H.pylori +ve
2. No. of pts with H.pylori –ve

The maximum number of patients (65) were in the range of 20-30 years of age and the mean age is 36±14.9 (table no.4). Among these 220 patients, 115 (52.30%) were males and 105 (47.7%) were females (table no.5). Table no.6 shows the symptomatic presentation of patients. Among 220, a maximum number of patients 208 (94.5%) were complaining of nausea/ and vomiting and abdominal pain. 89.5% (197) were having heart burn, 76.8% (169) were having loss of appetite and 71.8% (158) were having the complaint of indigestion.

**TABLE-4**

<table>
<thead>
<tr>
<th>Age Group</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-20</td>
<td>28</td>
<td>12.7</td>
</tr>
<tr>
<td>20-30</td>
<td>65</td>
<td>29.5</td>
</tr>
<tr>
<td>30-40</td>
<td>44</td>
<td>20.0</td>
</tr>
<tr>
<td>40-50</td>
<td>44</td>
<td>20.0</td>
</tr>
<tr>
<td>50-60</td>
<td>25</td>
<td>11.4</td>
</tr>
<tr>
<td>60-70</td>
<td>07</td>
<td>3.2</td>
</tr>
<tr>
<td>70-80</td>
<td>07</td>
<td>3.2</td>
</tr>
<tr>
<td>Total</td>
<td>220</td>
<td>100</td>
</tr>
<tr>
<td>Mean SD</td>
<td></td>
<td>36±14.9</td>
</tr>
</tbody>
</table>

**TABLE-5**

<table>
<thead>
<tr>
<th>Sex of Patients</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>115</td>
<td>52.3</td>
</tr>
<tr>
<td>Female</td>
<td>105</td>
<td>47.7</td>
</tr>
</tbody>
</table>

**TABLE-6**

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart burn</td>
<td>197</td>
<td>89.5</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>208</td>
<td>94.5</td>
</tr>
<tr>
<td>Indigestion</td>
<td>158</td>
<td>71.8</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>208</td>
<td>94.5</td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>169</td>
<td>76.8</td>
</tr>
</tbody>
</table>

These 220 patients were divide into 2 groups i.e. group A and group B of 110 patients each. Group A was prescribed Unani compound drug and group B was prescribed the placebo.

Table no.7 shows the comparative (pretreatment and post treatment) in symptomatology between group A and B. It was observed that the complaint of heart burn improved in 91.8% patients of group A, where as it improved only in 9.9% patients of group B. Complaint of nausea/vomiting improved in 94% patients of group A and it improved in just 12% of patients belonging to group B. Indigestion improved in 96.2% patients of group A and in group B it improved only in 8.9% patients. Abdominal pain was relieved in 92.5% patients of group A and just 5% of patients could get relief in group B. Complaint of loss of appetite was relieved in 92.3% patients of group A whereas in group B only 5.9% could get relief from the complaint of loss of appetite. In both the groups the difference of percentage in improvement is quite remarkable.

**TABLE-7**

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Group A n=110</th>
<th>Group B n=110</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Heart burn</td>
<td>98</td>
<td>8</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>100</td>
<td>6</td>
</tr>
<tr>
<td>Indigestion</td>
<td>80</td>
<td>3</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>107</td>
<td>8</td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>85</td>
<td>4</td>
</tr>
</tbody>
</table>

1. No. of patient before treatment
2. No. of patient after treatment
3. Improvement in percentage

Table no.8 shows the endoscopic changes in antral gastritis/generalized gastritis after 3 months of treatment in group A and group B. It was observed that after treatment with the Unani drug compound 96.34% patients got cure from antral/generalized gastritis in group B, whereas none of the patients could get relief in group B after taking placebo. For table no 8 we applied Yates corrected chi square test and its value was 174.748 (d.f.=1, p<0.0001) and the difference is highly significant.

**TABLE-8**

<table>
<thead>
<tr>
<th>Status of gastritis</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of patients</td>
<td>percentage</td>
</tr>
<tr>
<td>Cured</td>
<td>106</td>
<td>96.4</td>
</tr>
<tr>
<td>Not cured</td>
<td>4</td>
<td>3.6</td>
</tr>
</tbody>
</table>
Effect of Unani drug compound and Placebo after 3 months of therapy in eradication of Helicobacter pylori bacteria is shown in table no. 9.

<table>
<thead>
<tr>
<th>Groups</th>
<th>No. of patients who became H. pylori negative after treatment</th>
<th>No. of patients who remained H. pylori positive after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of patients</td>
<td>percentage</td>
</tr>
<tr>
<td>Group A</td>
<td>101</td>
<td>91.81</td>
</tr>
<tr>
<td>Group B</td>
<td>6</td>
<td>5.45</td>
</tr>
</tbody>
</table>

Among 110 patients of group A, 101 patients became H. pylori negative and 9 patients remained positive, hence in group A the Unani drug compound eradicated the H. pylori bacteria in 91.8% of patients. In group B, after 3 months just 6 patients became H. pylori negative and 104 patients remained positive thus placebo could not eradicate Helicobacter pylori in 94.54% patients. On applying Yates corrected Chi square test, its value was 160.774 (d.f.=1, p<0.0001) and the difference is highly significant.

4. DISCUSSION

The bacteria H. pylori has revolutionized the approach of acid peptic disease as it has been found to play an important role in gastritis, peptic ulcer disease and recently in gastric cancer [2],[75],[76]. The antral colonization with H. pylori organism has been reported from every corner of the world especially from developing and under developing countries [77]. Romshoo GH, et al [78] found the association between H. pylori infection to be 90% and in our study we found the association to be 88.7% which is almost similar.

The aim of this study was to demonstrate the effect of Unani drug compound containing “Glycyrrhiza glabra (Asl–us-soos), Plantago ovata (Asapghol musallam), Acacia arabica (Samghhe arabi) and Pistacia lenticus (Mastagi)” in the treatment of antral gastritis and eradicating H. pylori bacteria from the stomach, which is a major cause. Glycyrrhiza glabra (Asl–us-soos)/Licorice reduces stomach secretion, produces thick protective mucus for stomach lining which protect it from inflammation, gastritis and peptic ulceration [79], it contains flavonoids thus it possesses anti-inflammatory and antibacterial effect [80] and Krausse, R et al, in their study found that Licorice extract produced a potent effect against strain of H. pylori that are resistant against clarithromycin [81]. Marjan Rahnama et al in a study showed the eradicative effect of Licorice against H. pylori to be 70% [82]. The authors concluded that the study provides hope that Licorice can form the basis for an alternative treatment for H. pylori [83]. Plantago ovata (Asapghol musallam) water soluble seed husk polysaccharides promoted proliferation of human epithelial cells through growth factor receptors [84] and mucopolysaccharides derived from the husk of Plantago ovata showed wound cleansing and wound healing properties in guinea pigs [85], hence it is effective in healing of peptic ulcers and inflammation. In an in vitro study Castillo-Juarez et al and Nabati et al [86], [87] reported that Plantago ovata (Asapghol musallam) has anti-H.pylori activity. Acacia arabica (Samghe arabi) is shown to be protective against stress-induced gastric ulcer in vitro [88]. M. Amin et al [89] in an in vitro study found Acacia nilotica extract to be bactericidal against H.pylori and this anti-H.pylori activity may be attributed to the hydrolysable tannins, saponins, glycosides, phenols, terpenes and flavonoids [90]. Pistacia lenticus (Mastagi)/Mastic gum is cytoprotective and has mild anti secretory effect [91], it is effective for healing gastritis and duodenal ulcer [92], [93] and Mastic gum has shown anti-H.pylori effect not only in vitro but in clinical trial as well [94], [95], [96]. Among all these studies, most of them are done in vitro.

In our study we observed that the Unani drug compound relieved the symptoms effectively in experimental group compared to placebo control group in 3 months and post treatment endoscopy revealed that this combination of Unani drug effectively cured 96.4% patients with antral/generalized gastritis and it was found to be highly significant. Each drug among Glycyrrhiza glabra (Asl–us-soos), Plantago ovata (Asapghol musallam), Acacia Arabica (Samgh arabi) and Pistacia lenticus (Mastagi) has been proved to be effective in treating gastritis and to possess antibacterial effect against H.pylori bacteria and in our study we found that the experimental Unani drug compound eradicated the bacteria in 91.81% subjects and the results were highly significant.
5. CONCLUSION

There are various drugs in Unani system of medicine for the management of gastritis and which possess Anti-H.pylori effect as well as their efficacy had been confirmed through various in vitro studies but these drugs lack human studies. In our study we found the Unani drug compound containing Glycyrrhiza glabra (Asl–us-soos), Plantago ovata (Asapghol musallam), Acacia Arabica (Samghe arabii) and Pistacia lenticus (Mastagi) to be effective in treating antral gastritis and eradicating H.pylori bacteria and it is recommended to conduct more clinical trials to prove their efficacy and obtain more conclusive results.

REFERENCES


[63] R. Hussain, “Role of Qurs-e-Tabasheer in cases of endoscopically proved Gastritis and duodinitis.” M.S.


M. Kabiruddin, "Bayaae Kabeer", NM edn, Sheikh Mohammad Basheer and Sons Lahore, vol. 1&2, YNM.


K. H. Omayma, M.Y. Mohamed and E. Mona, “Possible protective effect of gum Arabic on experimentally...


